{"id":"W4254584811","doi":"10.1200/jco.2019.37.7_suppl.358","title":"BMS-986205, an indoleamine 2, 3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (nivo): Updated safety across all tumor cohorts and efficacy in advanced bladder cancer (advBC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Nivolumab; Medicine; Nausea; Internal medicine; Safety profile; Cancer; Oncology; Cohort; Immunotherapy; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003612908,0.0004257551,0.0006318089,0.0003303892,0.0001980884,0.0005249147,0.0003084816,0.0003688739,0.002268795],"category_scores_gemma":[0.0001939447,0.0001989013,0.000453501,0.0003562229,0.0002186555,0.0003539203,0.0001728675,0.001511529,0.0006867726],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005834264,"about_ca_system_score_gemma":0.0006518895,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007250147,"about_ca_topic_score_gemma":0.003032874,"domain_scores_codex":[0.9998709,0.00002736363,0.000008017635,0.00002429311,0.00004098385,0.00002845992],"domain_scores_gemma":[0.9998885,0.000009662341,0.00002827734,0.000009406972,0.00001412684,0.00004988789],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1026625,0.04675236,0.01846225,0.001277506,0.0009762486,0.0002754375,0.0002768354,0.003091571,0.3243444,0.0006105553,0.01483563,0.4864347],"study_design_scores_gemma":[0.1094951,0.5214043,0.1065993,0.0002170637,0.002161351,0.002437097,0.0002018946,0.006473046,0.1816774,0.0008348253,0.06837278,0.0001258157],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9879374,0.004703775,0.0007714088,0.0002932943,0.0001024781,0.0008053146,0.001438019,0.0001730276,0.003775434],"genre_scores_gemma":[0.9863452,0.003070879,0.002259314,0.000446454,0.00005588165,0.0005254608,0.003340992,0.00004096824,0.003914979],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002268795,"threshold_uncertainty_score":0.007589877,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03992822245600391,"score_gpt":0.4255002672715715,"score_spread":0.3855720448155676,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}